Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 7

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

767

HTML

5736

Tables (1-2)

146

Sum=6649

Publishing Process of This Article

Item

Count

Browse

904

Download

780

Sum=1684

Jul 27, 2013 (publication date) through Apr 26, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Jul 27, 2013; 5(7): 345-352
Published online Jul 27, 2013. doi: 10.4254/wjh.v5.i7.345

Table 2 Ongoing clinical trials for overcoming sorafenib resistance

Studies	Therapeutic strategies	Phases	Primary outcomes
Combinational therapy
NCT01271504	E7050 plus sorafenib vs sorafenib	Phase II	Adverse event
NCT01033240	CS-1008 plus sorafenib vs sorafenib	Phase II	TTP
NCT01539018	Tegafur-uracil plus sorafenib vs sorafenib	Phase II	TTP
NCT01272557	Doxorubicin plus sorafenib vs sorafenib	Phase II	TTP
NCT01015833	Doxorubicin plus sorafenib vs sorafenib	Phase III	OS
NCT01214343	Cisplatin/fluorouracil plus sorafenib vs sorafenib	Phase III	OS
Second-line treatments
NCT01507168	GC33 vs placebo	Phase II	PFS
NCT01273662	Axitinib	Phase II	SD
NCT00717756	Lenalidomide	Phase II	RR
NCT01545804	Lenalidomide	Phase II	SD
NCT01567930	Temsirolimus	Phase II	Disease progression
NCT01180959	Erlotinib plus bevacizumab	Phase II	PFS
NCT01140347	Ramucirumabplus BSC vs placebo plus BSC	Phase III	PFS
NCT01108705	Brivanib plus BSC vs placebo plus BSC	Phase III	OS
NCT00825955	Brivanib plus BSC vs placebo plus BSC	Phase III	OS
NCT01035229	Everolimus plus BSC vs placebo plus BSC	Phase III	OS

TTP: Time to progression; OS: Overall survival; SD: Stable disease; PFS: Progression-free survival; RR: Response rate; BSC: Best supportive care.

Citation: Zhai B, Sun XY. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 2013; 5(7): 345-352
URL: https://www.wjgnet.com/1948-5182/full/v5/i7/345.htm
DOI: https://dx.doi.org/10.4254/wjh.v5.i7.345